Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11161694 | 0.83 | PSIP1 (0.36) | ALDH1A1 | |
| SCHEMBL8932315 | 0.83 | TTR (0.36) | ALDH1A1POLB | |
| SCHEMBL211528 | 0.72 | ALDH1A1 (0.44) | ALDH1A1POLBPKM | |
| SCHEMBL558657 | 0.71 | MEN1 (0.38) | ALDH1A1 | |
| SCHEMBL5440477 | 0.71 | CA2 (0.38) | ALDH1A1 | |
| SCHEMBL2444608 | 0.71 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL10411212 | 0.71 | — | — | |
| SCHEMBL5000412 | 0.70 | — | — | |
| SCHEMBL16083927 | 0.70 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL558555 | 0.68 | PSMB8 (0.44) | ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2493894-B1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2493893-B1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-15 | — | — | EP | claimed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | claimed |
| US-8278320-B2 | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | claimed |
| EP-2493893-A1 | AZABICYCLO[2.2.1]HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | claimed |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | claimed |
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-27 | — | — | US | claimed |
| WO-2011056503-A1 | AZABICYCLO[2.2.1] HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-12 | — | — | WO | claimed |
| EP-2271650-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | claimed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | claimed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | claimed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | claimed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | claimed |
| US-3998803-A | TEXTILES | FIDELITY UNION TRUST COMPANY, EXECUTIVE TRUSTEE UNDER THE SANDOZ TRUST (US) | 1976-12-21 | — | — | US | claimed |
| CN-110430897-B | Conjugation unit and molecular construct comprising same | 免疫功坊股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-111194223-A | Drug molecules with better binding affinity to albumin | 免疫功坊股份有限公司 | 2020-05-22 | — | — | CN | disclosed |
| US-4032532-A | AZO DYES | SANDOZ LTD. (CH) | 1977-06-28 | — | — | US | disclosed |
| US-3998803-A | TEXTILES | FIDELITY UNION TRUST COMPANY, EXECUTIVE TRUSTEE UNDER THE SANDOZ TRUST (US) | 1976-12-21 | — | — | US | disclosed |
| US-3932366-A | FROM AMINOCARBOXYLIC ACIDS AND TRIAMINES, FIBER REACTIVE DYES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | BCAT2 3020/4885ALDH1A1 1082/4885POLB 2083/4885 |
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA2, CHRNA5 | BCAT2 3228/4885ALDH1A1 531/4885POLB 1439/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | BCAT2 3020/4885ALDH1A1 1082/4885POLB 2083/4885 |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA6, CHRNA5 | BCAT2 3207/4885ALDH1A1 1011/4885POLB 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.